{"id":"NCT05371652","sponsor":"Pfizer","briefTitle":"A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants","officialTitle":"A Multicenter, Open Label, Long-term Safety Study of BHV3000 for the Acute Treatment of Migraine in Chinese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-19","primaryCompletion":"2024-02-06","completion":"2024-02-06","firstPosted":"2022-05-12","resultsPosted":"2025-02-20","lastUpdate":"2025-02-20"},"enrollment":241,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Migraine"],"interventions":[{"type":"DRUG","name":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","otherNames":[]}],"arms":[{"label":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","type":"EXPERIMENTAL"}],"summary":"This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine","primaryOutcome":{"measure":"Treatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"From Day 1 of study treatment up to Week 52 of the treatment safety period","effectByArm":[{"arm":"Rimegepant 75 mg ODT","deltaMin":203,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":26,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=BHV3000-318"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":240},"commonTop":["COVID-19","Upper respiratory tract infection","Hyperuricaemia","Nasopharyngitis","Hyperlipidaemia"]}}